DF
Therapeutic Areas
Greenwich LifeSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GLSI-100 (GP2 + GM-CSF) | Prevention of recurrence in HLA-A*02+, HER2 3+ breast cancer (adjuvant setting) | Phase III |
Leadership Team at Greenwich LifeSciences
DM
Dr. Mothaffar F. Rimawi
Steering Committee Member
DW
Dr. William J. Gradishar
Steering Committee Member
DS
Dr. Sibylle Loibl
Steering Committee Member
DM
Dr. Miguel Martin
Steering Committee Member
DJ
Dr. Joyce A. O’Shaughnessy
Steering Committee Member
DH
Dr. Hope S. Rugo
Steering Committee Member
DL
Dr. Laura M. Spring
Steering Committee Member
DC
Dr. Cesar A. Santa-Maria
Steering Committee Member